Ignite Creation Date:
2024-10-26 @ 3:37 PM
Last Modification Date:
2024-10-26 @ 3:37 PM
Study NCT ID:
NCT06541314
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-06-13
Brief Title:
Fluzoparib Neoadjuvant Therapy for Ovarian Cancer
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Multicenter Single-Arm Clinical Study of Fluzoparib Monotherapy as Neoadjuvant Treatment for Advanced Epithelial Ovarian Cancer
Status:
RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is an interventional single-arm open-label clinical trial To evaluate the safety and efficacy of Fluzoparib as neoadjuvant therapy in patients with FIGO stage III and IV BRCA mutations or HRD positive epithelial ovarian cancer who cannot achieve R0 surgery as assessed by imaging Suidans CT score or laparoscopy Fagotti score or cannot tolerate surgery
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None